Ohio is currently home to 3189 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Genomic Analysis of Families With a History of Discordant Cancers
NCT04860453
Recruiting
The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and without cancer will be accrued to the study. Participants qualify to take part in this research study because someone in their family has been diagnosed with or because they themselves have a cancer diagnosis. Participants' DNA and other clinical information will be obtained from a blood sample in order to study the genetic basis of cancer an... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/11/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Discordant Cancers
Register for Updates
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251
Recruiting
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/11/2025
Locations: Cincinnati Eye Institute, Blue Ash, Ohio
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
NCT04847453
Recruiting
This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change \[translocation t(11;14)\]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: AL Amyloidosis
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
ALL
Ages:
Between 28 days and 18 years
Trial Updated:
04/11/2025
Locations: Research Site #102, Cincinnati, Ohio
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University Hospitals of Cleveland, Cleveland, Ohio
Conditions: Peripheral Vascular Diseases
Register for Updates
Project 2 Airway Potential Hydrogen (pH) in Asthma
NCT03617718
Recruiting
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/11/2025
Locations: University Hospitals Cleveland Medical Center - Asthma Research Center, Cleveland, Ohio
Conditions: Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Register for Updates
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796
Recruiting
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Gender:
ALL
Ages:
All
Trial Updated:
04/11/2025
Locations: Oncology Hematology Care, Inc., Cincinnati, Ohio
Conditions: Neoplasms
Register for Updates
Hairy Cell Leukemia Patient Data Registry
NCT02560883
Recruiting
The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Leukemia, Other
Register for Updates
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 Diabetes
NCT06865989
Recruiting
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) the... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
04/10/2025
Locations: University Hospitals Cleveland, Cleveland, Ohio
Conditions: Diabetes Mellitus, Type 1
Register for Updates
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683
Recruiting
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2025
Locations: Alkermes Investigational Site, Cincinnati, Ohio
Conditions: Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Register for Updates
I-InTERACT Preterm Parenting
NCT06767293
Recruiting
Many children born very preterm experience behavior problems, and existing resources for parenting these children are lacking. A pilot trial established the effectiveness of a preterm parenting intervention, I-Interact Preterm (I2P). This study proposes a three-arm randomized controlled trial (RCT) comparing the established seven-session I2P program, a microlearning delivery mode (I2P-Micro), and an internet resource comparison group (IRC). Outcomes will be assessed at pretreatment, post-treatme... Read More
Gender:
ALL
Ages:
Between 3 years and 8 years
Trial Updated:
04/10/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Child Behavior Problem, Preterm, Parent-Child Relations, Parenting
Register for Updates
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962
Recruiting
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Crohns Disease
Register for Updates